SARA O'CONNOR: Open Payments
NPI 1639519853 · BOISE, ID. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$616 in 16 payments from 10 companies in 2025. Trend: 2023 $539 · 2024 $641 · 2025 $616
Food & beverage: $616
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. | 2 | $243 |
| BridgeBio Pharma, Inc. | 2 | $96 |
| E.R. Squibb & Sons, L.L.C. | 4 | $82 |
| Novo Nordisk Inc | 2 | $57 |
| GENZYME CORPORATION | 1 | $29 |
| Lilly USA, LLC | 1 | $24 |
| Boston Scientific Corporation | 1 | $23 |
| Abbott Laboratories | 1 | $22 |
| Medtronic, Inc. | 1 | $22 |
| Novartis Pharmaceuticals Corporation | 1 | $19 |
Products named: REPATHA, Attruby, CAMZYOS, Wegovy, FABRAZYME, ZEPBOUND, General - Therapies, ASSURITY.
Industry payments across ID — which companies pay providers there.
